APA (7th ed.) Citation

L, A., M, R., M, L., I, M., I, L., ML, B., . . . AMC, R. (2025). Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024. Influenza and other respiratory viruses, 19(3), e70081. https://doi.org/10.1111/irv.70081

Chicago Style (17th ed.) Citation

L, Antunes, et al. "Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024." Influenza and Other Respiratory Viruses 19, no. 3 (2025): e70081. https://doi.org/10.1111/irv.70081.

MLA (9th ed.) Citation

L, Antunes, et al. "Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024." Influenza and Other Respiratory Viruses, vol. 19, no. 3, 2025, p. e70081, https://doi.org/10.1111/irv.70081.